Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Drugs In Development, 2021

According to the recently published report 'Neuropeptide Y Receptor Type 2 – Drugs In Development, 2021'; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.

The report 'Neuropeptide Y Receptor Type 2 – Drugs In Development, 2021' outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity and Epilepsy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)

– The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects

– The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

CombiGene AB

Gila Therapeutics Inc

Takeda Pharmaceutical Co Ltd

XL-protein GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved in Therapeutics Development

CombiGene AB

Gila Therapeutics Inc

Takeda Pharmaceutical Co Ltd

XL-protein GmbH

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles

CG-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GT-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYY-1119 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Discontinued Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones

Featured News & Press Releases

Mar 04, 2021: BioStock: CombiGene advances preclinically and recruits post-doc

Mar 01, 2021: The material from the first large-scale production of CG01 is now released for use in the final parts of the preclinical program

Feb 09, 2021: Interview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities’ positive response

Feb 03, 2021: Response from the Swedish and UK Pharmaceutical Regulatory Authorities confirms CombiGene’s plan for CG01’s final preclinical studies

Jan 18, 2021: With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01

Dec 14, 2020: With the recruitment of Martin Linhult, CombiGene is starting the process to strengthen the company in preparation for the clinical studies in the epilepsy project CG01

Oct 30, 2020: CombiGene comments the final preclinical steps

Oct 01, 2020: CombiGene one step closer to clinical trials

Sep 28, 2020: CombiGene launches large-scale production of CG01 for upcoming safety and biodistribution studies

Sep 15, 2020: CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy

Sep 11, 2020: CombiGene’s new agreement important for future clinical studies

Sep 10, 2020: CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene’s gene therapy CG01

Sep 10, 2020: CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene’s gene therapy CG01

Sep 03, 2020: CombiGene signs production agreement with Spanish gene therapy manufacturer Viralgen

Aug 18, 2020: Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by CombiGene AB, 2021

Pipeline by Gila Therapeutics Inc, 2021

Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Pipeline by XL-protein GmbH, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports